BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,390,471 | +1.3% | 190,429 | +6.0% | 0.01% | 0.0% |
| Q2 2023 | $15,190,104 | +4.1% | 179,722 | +4.0% | 0.01% | -16.7% |
| Q4 2022 | $14,597,092 | -6.0% | 172,808 | +226.1% | 0.01% | -14.3% |
| Q3 2022 | $15,528,000 | -10.5% | 52,998 | +8.2% | 0.01% | -12.5% |
| Q2 2022 | $17,356,000 | -18.0% | 48,988 | +3.5% | 0.01% | -20.0% |
| Q1 2022 | $21,156,000 | -19.5% | 47,317 | -8.4% | 0.01% | -28.6% |
| Q4 2021 | $26,297,000 | -56.3% | 51,630 | -57.6% | 0.01% | -48.1% |
| Q3 2021 | $60,161,000 | +67.3% | 121,883 | +52.1% | 0.03% | +50.0% |
| Q2 2021 | $35,965,000 | +35.9% | 80,114 | +22.7% | 0.02% | +5.9% |
| Q1 2021 | $26,459,000 | +14.6% | 65,308 | -5.3% | 0.02% | +13.3% |
| Q4 2020 | $23,091,000 | +5.5% | 68,967 | -19.3% | 0.02% | -16.7% |
| Q3 2020 | $21,887,000 | +203.5% | 85,433 | +228.6% | 0.02% | +157.1% |
| Q2 2020 | $7,211,000 | +46.0% | 25,999 | +0.4% | 0.01% | +16.7% |
| Q1 2020 | $4,940,000 | +5.4% | 25,891 | +21.3% | 0.01% | +50.0% |
| Q4 2019 | $4,685,000 | +109.5% | 21,340 | +86.7% | 0.00% | +100.0% |
| Q3 2019 | $2,236,000 | -4.0% | 11,429 | +2.4% | 0.00% | 0.0% |
| Q2 2019 | $2,328,000 | -7.2% | 11,163 | -11.6% | 0.00% | 0.0% |
| Q1 2019 | $2,508,000 | +38.6% | 12,630 | +1.0% | 0.00% | 0.0% |
| Q4 2018 | $1,810,000 | -32.6% | 12,503 | -5.0% | 0.00% | 0.0% |
| Q3 2018 | $2,684,000 | -3.2% | 13,155 | -29.8% | 0.00% | 0.0% |
| Q2 2018 | $2,773,000 | +6.2% | 18,740 | +8.4% | 0.00% | 0.0% |
| Q1 2018 | $2,611,000 | +22.8% | 17,290 | +5.3% | 0.00% | 0.0% |
| Q4 2017 | $2,126,000 | +96.7% | 16,412 | +83.6% | 0.00% | +100.0% |
| Q3 2017 | $1,081,000 | +2.8% | 8,939 | -0.1% | 0.00% | 0.0% |
| Q2 2017 | $1,052,000 | -7.8% | 8,952 | -20.2% | 0.00% | 0.0% |
| Q1 2017 | $1,141,000 | -8.2% | 11,223 | -4.9% | 0.00% | 0.0% |
| Q4 2016 | $1,243,000 | -5.3% | 11,798 | -1.5% | 0.00% | 0.0% |
| Q3 2016 | $1,312,000 | -2.5% | 11,980 | +0.3% | 0.00% | -50.0% |
| Q2 2016 | $1,346,000 | +44.9% | 11,940 | +21.5% | 0.00% | +100.0% |
| Q1 2016 | $929,000 | +11.4% | 9,825 | +6.1% | 0.00% | 0.0% |
| Q4 2015 | $834,000 | +20.2% | 9,263 | +23.3% | 0.00% | 0.0% |
| Q3 2015 | $694,000 | -5.1% | 7,513 | +1.1% | 0.00% | 0.0% |
| Q2 2015 | $731,000 | -4.2% | 7,429 | -2.3% | 0.00% | 0.0% |
| Q1 2015 | $763,000 | +7.8% | 7,606 | -0.9% | 0.00% | 0.0% |
| Q4 2014 | $708,000 | – | 7,672 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |